FDA Sets Advisory Committee Meeting to Discuss Testosterone Therapy Drugs
The FDA scheduled a meeting with the Drug Safety and Risk Management Advisory Committee and the Bone, Reproductive and Urologic Drugs Advisory Committee for September 17, 2014, to discuss testosterone replacement therapy drugs and cardiovascular risk. The joint meeting will allow for public comment along with advisory committee presentations.
This meeting comes after the agency issued a safety warning in June 2014 for patients taking testosterone replacement therapy drugs. The warning indicated a number of reports of venous blood clots such as deep vein thrombosis and pulmonary embolisms had been received.
The FDA cautioned the June warning was unrelated to the investigation the agency began in earlier in January after a study was published indicating that men on prescription testosterone demonstrated an increased risk for heart attack, stroke, and serious blood clots.
Lawsuits have been filed against makers of prescription testosterone products. Many men claim to have suffered serious injuries such as heart attacks, strokes, and serious blood clots like deep vein thrombosis and pulmonary embolisms after taking prescription testosterone drugs.
If you or someone you know has suffered a prescription testosterone injury, contact us. Our product liability attorneys have talked with hundreds of men who have taken drugs like Axiron, AndroGel, Androderm and others. Contact us now for a free case evaluation
